Osteoarthritis
📧 Sign up to get email alerts when something new happens for Osteoarthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-03Clinical Trial Update: Effect of Structured Info and Adapted Exercise in OA [NA]
A completed clinical trial investigating the effect of structured information and adapted exercise in osteoarthritis; results posted in 2022…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Testosterone Administration and ACL Reconstruction in Men [Phase 3]
Phase 3 clinical trial assessing testosterone administration in men undergoing ACL reconstruction; study completed with results posted.
-
CLINICAL_TRIALS withdrawal · 2022-02-18Clinical Trial Update: A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142) [Phase 4]
A Phase 4 clinical trial of etoricoxib in osteoarthritis participants not responding to analgesics was withdrawn.
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066) [Phase 3]
Phase 3 clinical trial update evaluating the safety of etoricoxib in osteoarthritis and rheumatoid arthritis has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007) [Phase 2]
Phase 2 trial update for etoricoxib (MK-0663-007) in osteoarthritis has been completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2022-02-15EMA Refused: Raylumis (tanezumab) — Pfizer Europe MA EEIG
The EMA refused the marketing authorization for Raylumis (tanezumab) from Pfizer Europe MA EEIG for osteoarthritis and pain, with a decision…
-
FDA approval · 2022-02-08FDA Approved: PIROXICAM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Piroxicam submitted by Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS trial_result · 2022-01-31Clinical Trial Update: NGA-01 Gel for the Treatment of Osteoarthritis With Joint Pain [Phase 2, Phase 3]
Clinical trial update for NGA-01 Gel in osteoarthritis with joint pain across Phase 2 and Phase 3 has completed.
-
FDA approval · 2022-01-11FDA Approved: CELECOXIB — Supplemental Application (NIVAGEN PHARMACEUTICALS, INC.)
The FDA approved a supplemental application for Celecoxib submitted by NIVAGEN Pharmaceuticals, Inc., for a generic Celecoxib product.
-
FDA approval · 2022-01-07FDA Approved: MELOXICAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for meloxicam, authorizing the generic NSAID product. This marks regulatory…
-
FDA approval · 2022-01-07FDA Approved: MELOXICAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for MELOXICAM (meloxicam) from Aurobindo Pharma Limited.
-
FDA approval · 2022-01-05FDA Approved: CELECOXIB — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for a generic celecoxib product (Celecoxib) under ANDA 202240.
-
CLINICAL_TRIALS trial_result · 2021-11-30Clinical Trial Update: Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System [Phase 4]
Post-approval Phase 4 trial update for the DURALOC Option Ceramic-on-Ceramic Hip Prosthesis System has been terminated.
-
CLINICAL_TRIALS trial_result · 2021-11-17Clinical Trial Update: A Trial of APPA in the Treatment of Knee Osteoarthritis [Phase 2]
Phase 2 clinical trial update for APPA in knee osteoarthritis has completed.
-
FDA approval · 2021-11-03FDA Approved: VOLTAREN ARTHRITIS PAIN — Supplemental Application (Haleon US Holdings LLC)
The FDA approved a supplemental application for Voltaren Arthritis Pain (diclofenac sodium) submitted by Haleon US Holdings LLC.
-
CLINICAL_TRIALS trial_result · 2021-10-18Clinical Trial Update: A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis [Phase 1, Phase 2]
A pilot study evaluating low-intensity ultrasound for treatment in osteoarthritis has completed phases 1 and 2 with results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-14Clinical Trial Update: Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment
Prospective multicenter non-interventional study in knee or hip osteoarthritis patients treated with Theraflex; completed with posted result…
-
FDA approval · 2021-08-24FDA Approved: DICLOFENAC SODIUM 1.5% — Supplemental Application (SOLA Pharmaceuticals)
The FDA approved a supplemental application for diclofenac sodium 1.5% topical from SOLA Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2021-08-19Clinical Trial Update: Roentgen Stereophotogrammetric Analysis (RSA) Trial Comparing Trabecular Metal Monoblock and Modular Tibial Components [Phase 4]
A phase 4 clinical trial comparing trabecular metal monoblock and modular tibial components using Roentgen Stereophotogrammetric Analysis (R…
-
CLINICAL_TRIALS trial_result · 2021-08-17Clinical Trial Update: Effects of tDCS and tUS on Pain Perception in OA of the Knee
The study assessed the effects of transcranial direct current stimulation (tDCS) and transcranial ultrasound (tUS) on pain perception in kne…
-
CLINICAL_TRIALS trial_result · 2021-08-04Clinical Trial Update: Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial [Phase 4]
Phase 4 randomized trial comparing leukocyte-rich PRP to leukocyte-poor PRP for knee cartilage degeneration in osteoarthritis.
-
FDA approval · 2021-08-02FDA Approved: DICLOFENAC SODIUM AND MISOPROSTOL — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Diclofenac Sodium and Misoprostol from Mylan Pharmaceuticals Inc.
-
FDA approval · 2021-07-19FDA Approved: VOLTAREN ARTHRITIS PAIN — Supplemental Application (Haleon US Holdings LLC)
The FDA approved a supplemental application for Voltaren Arthritis Pain (diclofenac sodium) submitted by Haleon US Holdings LLC.
-
FDA approval · 2021-07-15FDA Approved: DICLOFENAC SODIUM/MISOPROSTOL DICLOFENAC-SODIUM-MISOPROSTOL — Original Application (Micro Labs Limited)
FDA approved the original application for a generic fixed-dose combination of diclofenac sodium and misoprostol from Micro Labs Limited.
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis [Phase 2]
Phase 2 study assessing efficacy and safety of JointStem in osteoarthritis of the knee has completed with results posted.